MedPath

A Phase III study to evaluate the efficacy and safety of NRL-1 intranasally administered in Japanese pediatric patients with status epilepticus

Phase 3
Conditions
Japanese pediatric patients with status epilepticus or with seizures that may progress to status epi
Registration Number
JPRN-jRCT2031220265
Lead Sponsor
akagawa Eiji
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
15
Inclusion Criteria

Japanese pediatric patients with or at risk for status epilepticus

Exclusion Criteria

Patients who in the opinion of the Investigator or Subinvestigator, previously failed to respond to diazepam injected within 5 minutes after onset of seizures

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath